Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherReceivables RefundsShares Repurchased
Ratios

Indivior Pharmaceuticals (INDV) Accumulated Depreciation & Amortization (2021 - 2025)

Indivior Pharmaceuticals has reported Accumulated Depreciation & Amortization over the past 5 years, most recently at $10.0 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $10.0 million for Q4 2025, down 37.5% from a year ago — trailing twelve months through Dec 2025 was $10.0 million (down 37.5% YoY), and the annual figure for FY2025 was $10.0 million, down 37.5%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $10.0 million at Indivior Pharmaceuticals, up from $8.0 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for INDV hit a ceiling of $16.0 million in Q4 2022 and a floor of $4.0 million in Q2 2024.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $8.0 million (2025), compared with a mean of $9.2 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 166.67% in 2022 and later plummeted 37.5% in 2025.
  • Indivior Pharmaceuticals' Accumulated Depreciation & Amortization stood at $6.0 million in 2021, then skyrocketed by 166.67% to $16.0 million in 2022, then fell by 6.25% to $15.0 million in 2023, then grew by 6.67% to $16.0 million in 2024, then plummeted by 37.5% to $10.0 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $10.0 million (Q4 2025), $8.0 million (Q3 2025), and $5.0 million (Q2 2025) per Business Quant data.